- ICH GCP
- EU: s kliniska prövningsregister
Senaste försöken
EudraCT Number: 2022-001876-32 | Sponsor Protocol Number: SLN360-002 | Start Date: 2023-04-14 | ||||||||||||||||
Sponsor Name: Silence Therapeutics plc | ||||||||||||||||||
Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at... | ||||||||||||||||||
Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) SK (Ongoing) DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000788-30 | Sponsor Protocol Number: 1.2022 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Uzdrowisko Kamień Pomorski S.A. | ||||||||
Full Title: Evaluation of the effectiveness of Methocarbamol in the treatment of spasticity in people with spinal cord injury. | ||||||||
Medical condition: | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: PL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001181-10 | Sponsor Protocol Number: P003077 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Medical Center - University of Freiburg | ||||||||
Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand... | ||||||||
Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ... | ||||||||
|
||||||||
Population Age: Elderly | Gender: Male, Female | |||||||
Trial protocol: AT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001393-58 | Sponsor Protocol Number: T21-118 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Hagaziekenhuis | ||||||||
Full Title: POMPAE trial: Peri-Operative Magnesium infusion to Prevent Atrial fibrillation Evaluated. | ||||||||
Medical condition: Atrial fibrillation | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001297-63 | Sponsor Protocol Number: ML-ORI-201 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Melinta Therapeutics, LLC | ||||||||
Full Title: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects... | ||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: BG (Ongoing) LT (Ongoing) LV (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003065-38 | Sponsor Protocol Number: 1102-DMD-Pre-CT03 | Start Date: 2023-04-13 | |||||||||||
Sponsor Name: Antisense Therapeutics Limited | |||||||||||||
Full Title: A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by ... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002524-12 | Sponsor Protocol Number: BNZ-20-01-2022 | Start Date: 2023-04-13 | ||||||
Sponsor Name: AZAD Pharma AG | ||||||||
Full Title: A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Br... | ||||||||
Medical condition: GLAUCOMA , OCCULAR HYPERTENSION | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: BG (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002014-16 | Sponsor Protocol Number: VIR-MHB1-V200 | Start Date: 2023-04-12 | |||||||||||
Sponsor Name: Vir Biotechnology, Inc. | |||||||||||||
Full Title: A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL) | |||||||||||||
Medical condition: Chronic Hepatitis B Virus (HBV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002751-19 | Sponsor Protocol Number: 82160 | Start Date: 2023-04-11 | ||||||
Sponsor Name: Amsterdam UMC | ||||||||
Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients | ||||||||
Medical condition: Inflammatory Bowel Diseases | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002746-40 | Sponsor Protocol Number: VX22-864-108 | Start Date: 2023-04-11 | |||||||||||
Sponsor Name: Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks | |||||||||||||
Medical condition: Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |